Jennifer Anand: So this is my long overdue statement in support of Elephants and Tea I’m grateful and proud to be part of this organization.
Quoting Jennifer Anand, Columnist at on LinkedIn:
“Last week, Nick Giallourakis handed me this name tag. And I felt my usual pangs of apprehension to wear it. Was it pretentious to say “I’m on the Board”? Did I have anything to contribute? Should I try to hide it?
But then it struck me: I have chosen to spend my time, energy, and resources on this organization- why wouldn’t I want everyone to know about this incredible organization? I believe in their mission and the work they do and want to see them succeed. My life experiences have equipped me to help co-lead our Patient Advisory Committee and contribute there. I didn’t hide the tag, and wore it the entire weekend.
So this is my long overdue statement in support of Elephants and Tea I’m grateful and proud to be part of this organization. I’m thankful they value my voice and experiences, and I strive to ensure I represent the young adult cancer community to the best of my ability with them. I love the programming that is created with intention of inclusion. I guarantee everyone of us reading this knows someone whose life has been touched by cancer. Please consider checking out this organization and website. I’ve had the privilege of watching from the beginning, and I’m thrilled to continue along the journey as we celebrate 5 years.
All of us have different passions and issues that matter greatly to us, and I encourage you to devout some of your resources to supporting and promoting those causes.”
Source: Jennifer Anand/LinkedIn
-
12:46 30/11/23 | BlogJohanna Joyce: the Flashlight method
-
12:31 30/11/23 | InsightJeff Ryckman: Omitting RT in bulky early-stage cHL
-
07:45 30/11/23 | BlogAaron Goodman: Hemoglobin Dissociation Curve! Good stuff
-
12:31 30/11Jeff Ryckman: Omitting RT in bulky early-stage cHL
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows